{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:18:55Z","timestamp":1777349935930,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1038\/eye.2016.301","type":"journal-article","created":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T14:05:27Z","timestamp":1484921127000},"page":"650-656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom"],"prefix":"10.1038","volume":"31","author":[{"given":"F","family":"Alfaqawi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P L","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Elsherbiny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Chavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,20]]},"reference":[{"key":"BFeye2016301_CR1","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S0161-6420(94)31217-6","volume":"101","author":"SE Moss","year":"1994","unstructured":"Moss SE, Klein R, Klein BE . Ten-year incidence of visual loss in a diabetic population. Ophthalmology 1994; 101: 1061\u20131070.","journal-title":"Ophthalmology"},{"key":"BFeye2016301_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ophtha.2009.06.051","volume":"117","author":"R Klein","year":"2010","unstructured":"Klein R, Lee KE, Gangnon RE, Klein BE . The 25-year incidence of visual impairment in type 1 diabetes mellitus the wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology 2010; 117: 63\u201370.","journal-title":"Ophthalmology"},{"key":"BFeye2016301_CR3","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3109\/08820539909069543","volume":"14","author":"DA Antonetti","year":"1999","unstructured":"Antonetti DA, Lieth E, Barber AJ, Gardner TW . Molecular mechanisms of vascular permeability in diabetic retinopathy. Semin Ophthalmol 1999; 14: 240\u2013248.","journal-title":"Semin Ophthalmol"},{"key":"BFeye2016301_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.preteyeres.2013.02.001","volume":"34","author":"I Klaassen","year":"2013","unstructured":"Klaassen I, Van Noorden CJ, Schlingemann RO . Molecular basis of the inner blood\u2013retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res 2013; 34: 19\u201348.","journal-title":"Prog Retin Eye Res"},{"key":"BFeye2016301_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1755-3768.2008.01501.x","volume":"88","author":"R Ehrlich","year":"2010","unstructured":"Ehrlich R, Harris A, Ciulla TA, Kheradiya N, Winston DM, Wirostko B . Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol 2010; 88: 279\u2013291.","journal-title":"Acta Ophthalmol"},{"key":"BFeye2016301_CR6","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1096\/fj.03-1476fje","volume":"18","author":"AM Joussen","year":"2004","unstructured":"Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004; 18: 1450\u20131452.","journal-title":"FASEB J"},{"key":"BFeye2016301_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ophtha.2008.09.037","volume":"116","author":"H Funatsu","year":"2009","unstructured":"Funatsu H, Noma H, Mimura T, Eguchi S, Hori S . Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009; 116: 73\u201379.","journal-title":"Ophthalmology"},{"key":"BFeye2016301_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.preteyeres.2011.05.002","volume":"30","author":"J Tang","year":"2011","unstructured":"Tang J, Kern TS . Inflammation in diabetic retinopathy. Prog Retin Eye Res 2011; 30: 343\u2013358.","journal-title":"Prog Retin Eye Res"},{"key":"BFeye2016301_CR9","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","volume":"117","author":"MJ Elman","year":"2010","unstructured":"Diabetic Retinopathy Clinical Research Network Diabetic Retinopathy Clinical Research Network Elman MJ, Diabetic Retinopathy Clinical Research Network Aiello LP, Diabetic Retinopathy Clinical Research Network Beck RW, Diabetic Retinopathy Clinical Research Network Bressler NM, Diabetic Retinopathy Clinical Research Network Bressler SB et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064\u20131077 e35.","journal-title":"Ophthalmology"},{"key":"BFeye2016301_CR10","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/dme.12089","volume":"30","author":"LZ Heng","year":"2013","unstructured":"Heng LZ, Comyn O, Peto T, Tadros C, Ng E, Sivaprasad S et al. Diabetic retinopathy: pathogenesis, clinical grading, management and future developments. Diabetic Medicine 2013; 30: 640\u2013650.","journal-title":"Diabetic Medicine"},{"key":"BFeye2016301_CR11","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.ophtha.2008.06.015","volume":"115","author":"Diabetic Retinopathy Clinical Research N","year":"2008","unstructured":"Diabetic Retinopathy Clinical Research N. A randomized trial comparing intravitreal triamcinolone acetonide and focal\/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115: 1447\u20131459.","journal-title":"Ophthalmology"},{"key":"BFeye2016301_CR12","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s11892-012-0281-8","volume":"12","author":"MW Stewart","year":"2012","unstructured":"Stewart MW . Corticosteroid use for diabetic macular edema: old fad or new trend? Curr Diab Rep 2012; 12: 364\u2013375.","journal-title":"Curr Diab Rep"},{"key":"BFeye2016301_CR13","unstructured":"Ozurdex Summary of Product Characteristics. Available at: \n                    https:\/\/www.medicines.org.uk\/emc\/medicine\/23422\n                    \n                   (last accessed 3 March 2016)."},{"key":"BFeye2016301_CR14","unstructured":"ILUVIEN Summary of Product Characteristics. Available at: \n                    https:\/\/www.medicines.org.uk\/emc\/medicine\/27636\n                    \n                   (last accessed 9 November 2015)."},{"key":"BFeye2016301_CR15","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","volume":"119","author":"PA Campochiaro","year":"2012","unstructured":"Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012; 119: 2125\u20132132.","journal-title":"Ophthalmology"},{"key":"BFeye2016301_CR16","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.ophtha.2010.12.028","volume":"118","author":"PA Campochiaro","year":"2011","unstructured":"Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011; 118: 626\u2013635.","journal-title":"Ophthalmology"},{"key":"BFeye2016301_CR17","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","volume":"30","author":"NZ Gregori","year":"2010","unstructured":"Gregori NZ, Feuer W, Rosenfeld PJ . Novel method for analyzing snellen visual acuity measurements. Retina 2010; 30: 1046\u20131050.","journal-title":"Retina"},{"issue":"10","key":"BFeye2016301_CR18","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.ophtha.2014.04.019","volume":"121","author":"J Cunha-Vaz","year":"2014","unstructured":"Cunha-Vaz J, Ashton P, Iezzi R, Campochiaro P, Dugel PU, Holz FG et al. FAME Study Group.. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology 2014; 121 (10): 1892\u20131903.","journal-title":"Ophthalmology"},{"issue":"6","key":"BFeye2016301_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1136\/bjophthalmol-2015-307249","volume":"100","author":"C Pr\u00fcnte","year":"2016","unstructured":"Pr\u00fcnte C, Fajnkuchen F, Mahmood S, Ricci F, Hatz K, Studni\u010dka J et al. RETAIN Study Group.. Ranibizumab 0.5\u2009mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol 2016; 100 (6): 787\u2013795.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2016301_CR20","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","volume":"121","author":"DS Boyer","year":"2014","unstructured":"Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121: 1904\u20131914.","journal-title":"Ophthalmology"},{"key":"BFeye2016301_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1001\/archophthalmol.2009.109","volume":"127","author":"RW Beck","year":"2009","unstructured":"Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR et al. Three-year follow-up of a randomized trial comparing focal\/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127: 245\u2013251.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2016301_CR22","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1097\/IAE.0b013e318217d739","volume":"31","author":"J Googe","year":"2011","unstructured":"Googe J, Brucker AJ, Bressler NM, Qin H, Aiello LP, Antoszyk A et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal\/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina 2011; 31: 1009\u20131027.","journal-title":"Retina"},{"key":"BFeye2016301_CR23","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/j.ophtha.2013.02.018","volume":"120","author":"DG Callanan","year":"2013","unstructured":"Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013; 120: 1843\u20131851.","journal-title":"Ophthalmology"},{"key":"BFeye2016301_CR24","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1038\/eye.2015.214","volume":"29","author":"J Ramu","year":"2015","unstructured":"Ramu J, Yang Y, Menon G, Bailey C, Narendran N, Bunce C et al. A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study). Eye 2015; 29: 1603\u20131612.","journal-title":"Eye"},{"issue":"6","key":"BFeye2016301_CR25","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1136\/bjophthalmol-2015-307136","volume":"100","author":"LZ Heng","year":"2016","unstructured":"Heng LZ, Sivaprasad S, Crosby-Nwaobi R, Saihan Z, Karampelas M, Bunce C et al. A prospective randomised controlled clinical trial comparing a combination of repeated intravitreal Ozurdex and macular laser therapy versus macular laser only in centre-involving diabetic macular oedema (OZLASE study). Br J Ophthalmol 2016; 100 (6): 802\u2013807.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2016301_CR26","unstructured":"Taylor S, Chakravarthy U, Bailey C, presented on behalf of the ILUVIEN Registry Safety Study (IRISS) Investigators Group. Changes in intraocular pressure after ILUVIEN (190 micrograms fluocinolone acetonide)\u2014real-world experiences following usage in three European countries. Royal College of Ophthalmologist Annual Meeting; 4\u201326 May 2016. Birmingham, UK, 2016."},{"issue":"1","key":"BFeye2016301_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40123-016-0052-8","volume":"5","author":"FJ Go\u00f1i","year":"2016","unstructured":"Go\u00f1i FJ, Stalmans I, Denis P, Nordmann JP, Taylor S, Diestelhorst M et al. Elevated intraocular pressure after intravitreal steroid injection in diabetic macular edema: monitoring and management. Ophthalmol Ther 2016; 5 (1): 47\u201361.","journal-title":"Ophthalmol Ther"},{"key":"BFeye2016301_CR28","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/eye.2015.281","volume":"30","author":"Anil Kumar","year":"2016","unstructured":"Kumar Anil, AlFahad Q, Mitra A, Elsherbiny S, Lip PL . Intravitreal fluocinolone acetonide (Iluvien) for treatment of refractory diabetic macular oedema in vitrectomised eyes. Eye 2016; 30: 763\u2013764.","journal-title":"Eye"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/eye2016301.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2016301","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2016301.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:29:17Z","timestamp":1684430957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/eye2016301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,20]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["BFeye2016301"],"URL":"https:\/\/doi.org\/10.1038\/eye.2016.301","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,20]]},"assertion":[{"value":"19 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FA, PLL and RC declare no conflict of interest. SE is an Advisory Board Member of and speaker for Alimera Science, Bayer, Novartis, and Alcon. AM is an Advisory Board Member of Alimera Sciences. BM is an Advisory Board Member of and speaker for Alimera Science, Allergan, Bayer, Novartis, and ORAYA therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}